Lumexa Imaging Returns to Profitability in Q1 2026 with $252.5M Revenue, $0.02 EPS
LMRI sits 45% above its 52-week low of $7.23.
Summary
Lumexa Imaging Holdings, Inc. reported strong first-quarter 2026 results, achieving a net income of $1.7 million, or $0.02 diluted EPS, a significant swing from a net loss of $(7.7) million in the prior-year quarter. Revenue increased 3.1% year-over-year to $252.5 million, driven by same-center growth and new de novo centers. This positive earnings report follows the company's 2025 financial results, which showed increased revenue and reduced net loss, indicating continued operational improvement. The return to profitability and consistent revenue growth are material positive developments for the company, suggesting effective execution of its strategy to expand its outpatient imaging footprint and leverage higher-margin advanced imaging services. Investors will be watching for sustained profitability and further details on the impact of technology investments on future margins.
At the time of this announcement, LMRI was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $7.23 to $19.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.